Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

VIRION

Financiado

Cerrado

Viruses Immune stimulation and RNA Interference in Oncology Network

The Viruses, Immune stimulation and RNA Interference in Oncology Network (VIRION) is focused on the execution of an internationally competitive cancer research project focused on the development of a novel therapeutic regime by co... ver más

30/09/2019

STICHTING AMSTERDA...

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 6 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-09-30

MSCA-ITN-2014-EID: Marie Skłodowska-Curie Innovative T...

I+D

Cerrada hace 10 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

6 Participantes

STICHTING AMSTERDAM UMC

510.75K€ | Lider

STICHTING VU

N.D. | Participante

TILT BIOTHERAPEUTICS OY

538.29K€ | Participante

Lilly Deutschland GmbH

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2019-109102RA-I00 NUEVAS ESTRATEGIAS PARA SUPERAR LAS LIMITACIONES DE LA TERAP... 145K€ Cerrado

RIPECROP RNA-based cancer ImmunotheraPeutics to Enhance CROssPrimming 3M€ Cerrado

CANCERNA RNA PROCESSING FOR ANTI-CANCER IMMUNOTHERAPY 6M€ Cerrado

VIRAL&IMMUNE THERAPY Breaking Tolerance Combination of Virotherapy and Immunoth... 154K€ Cerrado

EUIN2013-51221 PREPARACION DE PROPUESTA PARA HORIZONTE2020CUREMYELOMA 15K€ Cerrado

Duración del proyecto: 52 meses Fecha Inicio: 2015-05-13
Fecha Fin: 2019-09-30

Líder del proyecto

STICHTING AMSTERDAM UMC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The Viruses, Immune stimulation and RNA Interference in Oncology Network (VIRION) is focused on the execution of an internationally competitive cancer research project focused on the development of a novel therapeutic regime by combining immune therapy with oncolytic virotherapy and RNA interference techniques. Recent clinical successes have shown the immune system to be a powerful ally in the fight against cancer. While surgery, chemotherapy and radiation therapy remain the first lines of treatment for most tumors, immunotherapy regimens have had astonishing clinical successes. Furthermore, recent studies have shown that pre-existing lymphocytic infiltration of tumors is associated with superior prognostic outcomes in a variety of cancers and might improve cancer therapies targeting immune checkpoints. A recent development in the immunotherapy field is adoptive cell therapy (ACT). In ACT lymphocytes from cancer patients are expanded ex vivo into more favorable numbers, they can be modified genetically or stimulated to relieve immune suppression and infused back into the patient. In clinical trials, ACT has resulted in anti tumor responses. However, immune suppression in the tumor microenvironment limits the efficacy of immunotherapy and remains a major hurdle. We aim to potentiate the antitumor immune reaction in the tumor microenvironment through the combination of immune therapy and oncolytic virotherapy. Oncolytic viruses are developed to specifically target and destroy tumor cells. In pre-clinical models, oncolytic adenoviruses have proven a powerful tool in the elimination of tumors, not only by their direct lytic effects but also by their triggering of a subsequent tumor inflammation and enhanced lymphocytic infiltration. VIRION will address how these immune responses can be further enhanced by addition of immune modulating factors and/or siRNA targeting tumor genes that play an immune suppressive role in the tumor micro environment.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores